Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate

ACS Medicinal Chemistry Letters

Volumn 7, Issue 9, 2016, Pages 862-867

  Evans, Catherine A ^a   Liu, Tao ^a   Lescarbeau, André ^a   Nair, Somarajan J ^a   Grenier, Louis ^a   Pradeilles, Johan A ^a   Glenadel, Quentin ^a   Tibbitts, Thomas ^a   Rowley, Ann M ^a,b   Dinitto, Jonathan P ^a   Brophy, Erin E ^a   O'Hearn, Erin L ^a   Ali, Janid A ^a   Winkler, David G ^a   Goldstein, Stanley I ^a   O'Hearn, Patrick ^a   Martin, Christian M ^a   Hoyt, Jennifer G ^a   Soglia, John R ^a   Cheung, Culver ^a   Pink, Melissa M ^a   Proctor, Jennifer L ^a   Palombella, Vito J ^a   Tremblay, Martin R ^a   Castro, Alfredo C ^a,c   more..

^a Infinity Pharmaceuticals Inc   (United States)

^b ABBVIE INC   (United States)

^c Surface Oncology   (United States)

Author keywords

immuno oncology; IPI 549; isoform selectivity; neutrophil migration; phosphoinositide 3 kinase; PI3K gamma inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 8; IPI 549; LIPID; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL MIGRATION; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPID ANALYSIS; MALE; METABOLIC STABILITY; MOUSE; NEUTROPHIL; NONHUMAN; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; SOLID TUMOR;

EID: 84986334019     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.6b00238     Document Type: Article

References (29)

1. Cantley, L. C. The phosphoinositide 3-kinase pathway Science 2002, 296, 1655-1657 10.1126/science.296.5573.1655
2. Vanhaesebroeck, B.; Whitehead, M. A.; Pineiro, R. Molecules in medicine mini-review: isoforms of PI3K in biology and disease J. Mol. Med. 2016, 94, 5-11 10.1007/s00109-015-1352-5
3. Hawkins, P. T.; Stephens, L. R. PI3K signaling in inflammation Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2015, 1851, 882-897 10.1016/j.bbalip.2014.12.006
4. Thorpe, L. M.; Yuzugullu, H.; Zhao, J. J. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting Nat. Rev. Cancer 2015, 15, 7-24 10.1038/nrc3860
5. Rommel, C.; Camps, M.; Ji, H. PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 2007, 7, 191-201 10.1038/nri2036
6. Banham-Hall, E.; Clatworthy, M. R.; Okkenhaug, K. The therapeutic potential for PI3K inhibitors in autoimmune and rheumatic diseases Open Rheumatol. J. 2012, 6, 245-258 10.2174/1874312901206010245
7. Sasaki, T.; Irie-Sasaki, U.; Jones, R. G.; Oliveira-do-Santos, A. J.; Stanford, W. L.; Bolon, B.; Wakeham, A.; Itie, A.; Bouchard, D.; Kozieradzki, I.; Joza, N.; Mak, T. W.; Ohashi, P. S.; Suzuki, A.; Penninger, J. M. Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration Science 2000, 287, 1040-1046 10.1126/science.287.5455.1040
8. Hirsch, E.; Katanaev, V. L.; Garlanda, C.; Azzolino, O.; Pirola, L.; Silengo, L.; Sozani, S.; Mantovani, A.; Altruda, F.; Wymann, M. P. Central role for G protein-coupled phosphoinositide 3-kinase in inflammation Science 2000, 287, 1049-1053 10.1126/science.287.5455.1049
9. Schmid, M. C.; Avraamides, C. J.; Dippold, H. C.; Franco, I.; Foubert, P.; Ellies, L. G.; Acevedo, L. M.; Manglicmot, J. R. E.; Song, X.; Wrasidlo, W.; Blair, S. L.; Ginsberg, M. H.; Cheresh, D. A.; Hirsch, E.; Field, S. J.; Varner, J. A. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3K γ, a single convergent point promoting tumor inflammation and progression Cancer Cell 2011, 19, 715-727 10.1016/j.ccr.2011.04.016
10. Joshi, S.; Singh, A. R.; Zulcic, M.; Durden, D. L. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1alpha and HIF2alpha stability and tumor growth, angiogenesis, and metastasis Mol. Cancer Res. 2014, 12, 1520-1531 10.1158/1541-7786.MCR-13-0682
11. Gunderson, A. J.; Kaneda, M. M.; Tsujikawa, T.; Nguygen, A. V.; Affara, N. I.; Ruffell, B.; Gorjestani, S.; Liudahl, S. M.; Truitt, M.; Olson, P.; Kim, G.; Hanahan, D.; Tempero, M. A.; Sheppard, B.; Irving, B.; Chang, B. Y.; Varner, J. A.; Coussens, L. M. Bruton tryrosine kinase-dependent immune cell cross-talk drives pancreas cancer Cancer Discovery 2016, 6, 270-285 10.1158/2159-8290.CD-15-0827
12. Rivera, L. B.; Meyronet, D.; Hervieu, V.; Frederick, M. J.; Bergsland, E.; Bergers, G. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy Cell Rep. 2015, 11, 577-591 10.1016/j.celrep.2015.03.055
13. De Palma, M.; Lewis, C. E. Macrophage regulation of tumor responses to anticancer therapies Cancer Cell 2013, 23, 277-286 10.1016/j.ccr.2013.02.013
14. Cushing, T. D.; Metz, D. P.; Whittington, D. A.; McGee, L. R. PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases J. Med. Chem. 2012, 55, 8559-8581 10.1021/jm300847w
15. Bergamini, G.; Bell, K.; Shimamura, s.; Werner, T.; Cansfield, A.; Mueller, K.; Perrin, J.; Tau, C.; Ellard, K.; Hopf, C.; Doce, C.; Leggate, D.; Mangano, R.; Mathieson, T.; O'Mahony, A.; Plavec, I.; Rharbaoui, F.; Savitski, M. M.; Ramsden, N.; Hirsch, E.; Drewes, G.; Rausch, O.; Bantscheff, M.; Neubauer, G. A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation Nat. Chem. Biol. 2012, 8, 576-582 10.1038/nchembio.957
16. Sunose, M.; Bell, K.; Ellard, K.; Bergamini, G.; Neubauer, G.; Werner, T.; Ramsden, N. Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease Bioorg. Med. Chem. Lett. 2012, 22, 4613-4618 10.1016/j.bmcl.2012.05.090
17. Leahy, J. W.; Buhr, C. A.; Johnson, H. W. B.; Kim, B. G.; Baik, T.; Cannoy, J.; Forsyth, T. P.; Jeong, J. W.; Lee, M. S.; Ma, S.; Noson, K.; Wang, L.; Williams, M.; Nuss, J. M.; Brooks, E.; Foster, P.; Goon, L.; Heald, N.; Holst, C.; Jaeger, C.; Lam, S.; Lougheed, J.; Nguyen, L.; Plonowski, A.; Song, J.; Stout, T.; Wu, X.; Yakes, M. F.; Yu, P.; Zhang, W.; Lamb, P.; Raeber, O. Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors J. Med. Chem. 2012, 55, 5467-5482 10.1021/jm300403a
18. Roller, A.; Perino, A.; Dapavo, P.; Soro, E.; Okkenhaug, K.; Hirsch, E.; Ji, H. Blockade of phosphatidylinositol 3-kinase (PI3K) δ or PI3Kγ reduces IL-17 and ameliorates imiquimod-induced psoriasis-like dermatitis J. Immunol. 2012, 189, 4612-4620 10.4049/jimmunol.1103173
19. Oka, Y.; Yabuuchi, T.; Oi, T.; Kuroda, S.; Fujii, Y.; Ohtake, H.; Inoue, T.; Wakahara, S.; Kimura, K.; Fujita, K.; Endo, M.; Taguchi, K.; Sekiguchi, Y. Discovery of N-{5-[3-(3-hydroxypiperdin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase γ inhibitor for the treatment of inflammatory diseases Bioorg. Med. Chem. 2013, 21, 7578-7583 10.1016/j.bmc.2013.10.042
20. Bruce, I.; Akhlaq, M.; Bloomfield, G. C.; Budd, E.; Cox, B.; Cuenoud, B.; Finan, P.; Gedeck, P.; Hatto, J.; Hayler, J. F.; Head, D.; Keller, T.; Kirman, L.; Leblanc, C.; Grand, D. L.; McCarthy, C.; O'Connor, D.; Owen, C.; Oza, M. S.; Pilgrim, G.; Press, N. E.; Sviridenko, L.; Whitehead, L. D. Development of isoform selective PI3K-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway Bioorg. Med. Chem. Lett. 2012, 22, 5445-5450 10.1016/j.bmcl.2012.07.042
21. Collier, P. N.; Martinez-Botella, G.; Cornebise, M.; Cottrell, K. M.; Doran, J. D.; Griffith, J. P.; Mahajan, S.; Maltais, F.; Moody, C. S.; Huck, E. P.; Wang, T.; Aronov, A. M. Structural basis for isoform selectivity in a class of benzothiazole inhibitors of phosphoinositide 3-kinase γ J. Med. Chem. 2015, 58, 517-521 10.1021/jm500362j
22. Collier, P. N.; Messersmith, D.; Le Tiran, A.; Bandarage, U. K.; Boucher, C.; Come, J.; Cottrell, K. M.; Damagnez, V.; Doran, J. D.; Griffith, J. P.; Khare-Pandit, S.; Krueger, E. B.; Ledeboer, M. W.; Ledford, B.; Liao, Y.; Mahajan, S.; Moody, C. S.; Roday, S.; Wang, T.; Xu, J.; Aronov, A. M. Discovery of highly isoform selective thiazolopiperidine inhibitors of phosphoinositide 3-kinase γ J. Med. Chem. 2015, 58, 5684-5688 10.1021/acs.jmedchem.5b00498
23. Boyd, M. J.; Aronov, A.; O'Dowd, H.; Green, J. A selective inhibitor of phosphatidylinositol 3-kinase-gamma. WO 2015/048318.
24. Winkler, D. G.; Faia, K. L.; DiNitto, J. P.; White, K. F.; Brophy, E. E.; Ping, M. M.; Proctor, J. L.; Lussier, J.; Martin, C. M.; Hoyt, J. G.; Tillotson, B.; Murphy, E. L.; Lim, A. R.; Thomas, B. D.; MacDougall, J. R.; Ren, P.; Liu, Y.; Li, L.-S.; Jessen, K. A.; Fritz, C. C.; Dunbar, J. L.; Porter, J. R.; Rommel, C.; Palombella, V. J.; Changelian, P. S.; Kutok, J. L. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppressed activity in autoimmune and inflammatory disease models Chem. Biol. 2013, 20, 1364-1374 10.1016/j.chembiol.2013.09.017
25. Knight, Z. A.; Gonzalez, B.; Feldman, M. E.; Zunder, E. R.; Goldenberg, D. D.; Williams, O.; Loewith, R.; Stokoe, D.; Balla, A.; Toth, B.; Balla, T.; Weiss, W. A.; Williams, R. L.; Shokat, K. M. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling Cell 2006, 125, 733-747 10.1016/j.cell.2006.03.035
26. Berndt, A.; Miller, S.; Williams, O.; Le, D. D.; Houseman, B. T.; Pacold, J. I.; Gorrec, F.; Hon, W.-C.; Liu, Y.; Rommel, C.; Gaillard, P.; Ruckle, T.; Schwarz, M. K.; Shokat, K. M.; Shaw, J. P.; Williams, R. L. The p100 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors Nat. Chem. Biol. 2010, 6, 117-124 10.1038/nchembio.293
27. Reif, K.; Okkenhaug, K.; Sasaki, T.; Penninger, J. M.; Vanhaesebroeck, B.; Cyster, J. G. Cutting edge: Differential roles for phosphoinositide 3-kinases, p110γ and p110δ, in lymphocyte chemotaxis and homing J. Immunol. 2004, 173, 2236-2240 10.4049/jimmunol.173.4.2236
28. Kutok, J.; Ali, J.; Brophy, E.; Castro, A.; DiNitto, J.; Evans, C.; Faia, K.; Goldstein, S.; Kosmider, N.; Lescarbeau, A.; Liu, T.; Martin, C.; McGovern, K.; Nair, S.; Pink, M.; Proctor, J.; Rausch, M.; Sharma, S.; Soglia, J.; Tchaicha, J.; Tremblay, M.; Villegas, V.; White, K.; Winker, D.; Palombella, V. The Potent and Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor, IPI-549, Inhibits Tumor Growth in Murine Syngeneic Solid Tumor Models through Alterations in the Immune Suppressive Microenvironment. In CRI-CIMT-EATI-AACR-The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, New York, Sept. 16-19, 2015.
29. NCT02637531: A dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IPI-549. www.clinicaltrials.gov.